Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.

Jordi RemonF TabbòB JimenezA CollazoJ de CastroS Novello

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)

Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients' outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
advanced non small cell lung cancer
small cell lung cancer
healthcare
prognostic factors
stem cells
gene expression
clinical trial
dna methylation
single cell
study protocol
epidermal growth factor receptor
health insurance
combination therapy